FindTrial
Sign In

A multicenter observational study of TAS-102 and regorafenib in patients with metastatic colorectal cancer

A multicenter observational study of TAS-102 and regorafenib in patients with metastatic colorectal cancer - A multicenter observational study of TAS-102 and regorafenib in patients with metastatic colorectal cancer

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000022276
Enrollment
50
Registered
2016-05-12
Start date
2015-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

None listed

Sponsors

Omori Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histologically proven Adenocarcinoma of colorectal cancer 2. Prior chemotherapy with more than two regimens 3. Written informed consent 4. Age under 20 years old at the time of informed consent 5. Patients are able to take medications orally.

Exclusion criteria

Exclusion criteria: 1. Prior therapy with TAS-102 or regorafenib 2. Inappropriate for the study in the option of the investigator

Design outcomes

Primary

MeasureTime frame
EuroQol 5 Dimension-5L (EQ5D-5L)—

Secondary

MeasureTime frame
Quality-adjusted life year (QALY) Incremental cost-utility ratio (ICUR) Progression free survival (PFS) Overall survival (OS) Response rate (RR) Disease control rate (DCR) Safety To investigate the reason for treatment selection Analysis of factor what patients were unable to choose the treatment by themselves—

Countries

Japan

Contacts

Public ContactEthics committee

Omori Red Cross Hospital Ethics committee

jinji@omori.jrc.or.jp03-3775-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026